Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global intravenous immunoglobulin market size was estimated at USD 11.98 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2023 to 2030. The growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of intravenous immunoglobulin (IVIG) treatments, and rising use of off-label indications are the key drivers of the market. The rising number of patients with immunodeficiency disorders is the primary cause for the development of IVIG preparations. The global market is expanding rapidly because of an increasing number of patients with bleeding issues, and an increasing number of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients. Furthermore, increased investment in the healthcare industry is assisting in the growth of the IVIg market. Additionally, the growing number of patients suffering from autoimmune illnesses and other pathological conditions is fueling market expansion for IVIg products.

The COVID-19 pandemic, which is currently in its last stages, is expected to boost the worldwide intravenous immunoglobulin market. According to a December 2020 research called "COVID-19 in patients with primary and secondary immunodeficiency: The U.K. experience, 70 percent of 100 people with symptomatic secondary immunodeficiency (SID), primary immunodeficiency (PID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus, and 59 percent were admitted to hospitals, with 8 percent dying. As a result, because immunocompromised people are more likely to get COVID-19, the market for intravenous immunoglobulin therapy is predicted to expand during the pandemic.

Aside from the economic crisis, COVID-19 has caused substantial issues for patients with mental and neurological disorders due to their increased susceptibility to infection. An uncommon but deadly illness known as MIS-C (multi-system inflammatory syndrome) has been documented in numerous places among the younger population. Many medical professionals have been evaluating the efficacy of IVIg injection for COVID-19 patients. For instance, in April 2021, Grifols, S.A. a key provider of plasma-derived medicines contributed to a research study in collaboration with both the NIH and NIAID, to analyze an intravenous anti-SARS-CoV-2 hyperimmune globulin among outpatients, intravenous immunoglobulin dynamics in the forecast period.

According to the W.H.O, currently, there are over 50 different Primary Immune Deficiency (PID’s) such as specific antibody deficiency, X-lined hypo-gamma-globulinemia, and others. PIDs include 176 different types of rare hereditary disorders. According to the U.S. National Library of Medicine and National Institute of Health, approximately 6 million patients are suffering from PID worldwide. Growing incidences of these diseases are expected to boost the demand for immunoglobulin therapies over the forecast period.

The demand for IVIG therapies for the treatment of acquired and primary immunodeficiency diseases is increasing as it is the most effective & the only available treatment option. Moreover, sedentary lifestyle habits, including consumption of saturated fats salt, & sugars, less physical activities, and high alcohol consumption have led to an increase in the prevalence of these diseases. The rising prevalence of lifestyle-associated disorders such as obesity & antibody deficiency disorders are the factors expected to drive the growth.

According to NIH data, over 500,000 persons in the U.S. suffer from more than 200 distinct types of primary immunodeficiency diseases (PIDDs). The rising prevalence of primary and acquired immunodeficiency illnesses including AIDS and X-linked hypogammaglobulinemia is projected to increase demand for immunoglobulin therapy during the forecast period.

Furthermore, the rising cost of IVIG therapy is projected to be a significant barrier to market expansion. Immunoglobulin infusions are typically given once every 3 to 4 weeks, and the therapy is ongoing around12-16 sessions yearly. The estimated cost of IVIG is USD 73.89 per gram, with a total cost of USD 10,000 depending on the severity of the illness. Immunoglobulin replacement treatments are long-term therapies that typically last 6 months. As per the ABIM Foundation, the expense of IgG treatment therapy exceeds USD 30,000 a year.

Application Insights

In 2022, immunodeficiency diseases dominated the market with a revenue share of over 20.30% owing to the increasing incidence of primary and acquired immunodeficiency diseases (PID & AID). PID & AID need to be treated with IV antibiotics to clear the infections. IVIG replacement therapy is the best available alternative for the treatment of immunodeficiency diseases. Hence the business is expected to show steady growth in the coming years.

Chronic Inflammatory demyelinating polyneuropathy (CIDP) segment held the second-largest share of the IVIG market on the basis of application. It is usually found in patients with diabetes mellitus. The treatment of CIPD involves the use of immunosuppressive drugs, steroids, and plasmapheresis. IVIG is an effective and long-lasting alternative to these methods. The associated benefits such as safety, minimally invasive and user-friendly treatment option are the factors contributing to the development of the industry.

Hypogammaglobulinemia. accounted for the third-largest share of the industry. This can be attributed to the owing to increasing incidences of primary immunodeficiency diseases (PID) worldwide. It is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs).

The Kawasaki disease segment is expected to exhibit lucrative growth owing to rising incidences of Kawasaki disease in children and rising demand for IVIG procedures for its treatment. The alternative for IVIG therapy is steroids which have more side effects; hence the penetration of IVIG therapies for the treatment of Kawasaki disease is expected to grow in the coming years. Moreover, factors such as increasing patient awareness levels and rising incidence of antibody deficiency diseases, and are expected to boost the demand for IVIG therapy consequentially driving the growth of this segment.

Distribution Channel Insights

The hospital pharmacy segment dominated the market with a revenue share of over 57.83% in 2022 owing to the large network of hospitals and the convenient range of products that are easily accessible through hospital pharmacies. Moreover, the growing incidence of primary immune deficiencies and hepatitis C, and other diseases as well has resulted in an increment in the number of hospitalizations worldwide, expanding the customer preference for hospital pharmacies. Furthermore, hospitals offer fast reimbursement, treatment, and proper care to a large number of patients, enabling a surge in the prevalence of patients selecting hospital pharmacies.

The specialty pharmacy segment is anticipated to grow significantly during the forecast period since specialty pharmacies enable easy treatment at home. Specialty drugs are an important and dynamic part of the pharmacy business as a result the number of licensed specialty drugs is increasing rapidly, which is driving the specialty pharmacy segment during the forecast period.

Regional Insights

North America dominated the overall market in 2022 with a revenue share of 46.51%. The increasing level of awareness pertaining to products involved in the treatment of immunodeficiency diseases, rising inclination of clinicians towards these therapies, and growing healthcare expenditure are the key factors contributing to the market growth.Furthermore, the growing administration of IVIG therapies for the treatment of illness, the existence of established healthcare as well as research infrastructure, and the rapidly increasing number of product approvals from the U.S. FDA are some of the factors anticipated to contribute to the region's revenue growth.

Changing lifestyles and the rising geriatric population prone to chronic diseases are some of the factors contributing to the growth of this industry. In addition, increasing incidences of PID are expected to present this market with future growth opportunities. In the U.S., autoimmune illnesses are the third most prevalent cause of chronic illness. Since many autoimmune disorders are uncommon, the National Institutes of Health predicts that diseases affect between 5% and 8% of the U.S. population. Autoimmune illnesses are becoming more common for unclear causes. the number is expected to grow over the forecast period.

The Asia Pacific is anticipated to exhibit lucrative growth over the forecast period as a consequence of increasing awareness and potential opportunities for the adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies coupled with a growing geriatric population. Other factors contributing to the development of this business are emerging economies, growing healthcare spending, and the rapidly growing immunoglobulin market. In addition, rising incidences of immune disorders, awareness levels pertaining to intravenous & subcutaneous immunoglobulin therapies, and improving healthcare facilities are anticipating further growth in the near future.

Key Companies & Market Share Insights

This industry is witnessing a significant boost owing to the growing number of FDA approvals. Owing to this, a number of local and international players are investing in the IVIG business. For instance, in March 2023, Kamada Ltd. received approval from the U.S. FDA to manufacture Cytomegalovirus Immune Globulin Intravenous [Human] (CMV-IGIV) at its site in Israel. This FDA approval marks the successful completion of the technology transfer process for CYTOGAM from CSL Behring. Kamada's business will benefit from the acquired portfolio of 4 FDA-approved IgGs, and they anticipate further development from these products in upcoming years. The company plans to begin commercial manufacturing of CYTOGAM at its Israeli facility soon, which will enhance the facility's efficiency and utilization.

Market players are adopting various strategies such as mergers and acquisitions, distribution, and other collaborative agreements to gain a greater share by increasing their market penetration. For instance, on in April 2022, Grifols S.A. completed its purchase of Biotest, a significant and transformative deal that will drive growth and innovation. Grifols' purchase of Biotest AG allows it to accelerate and extend its product range, boost patient access to plasma medicines, operate the biggest private European network of plasma facilities (87 sites), and drive revenue growth and margin development. Some of the key players in the global intravenous immunoglobulin market include:

• Biotest AG

• Baxter International Inc.

• Octapharma AG

• LFB Biotechnologies

• Grifols SA

• CSL Behring

• China Biologics Products Inc.

• Kedrion Biopharma

• BDI Pharma Inc.

Intravenous Immunoglobulin Market Report Scope 

Global Intravenous Immunoglobulin Market Report Segmentation

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2023 to 2030. For the purpose of this study, Grand View Research has segmented the global intravenous immunoglobulin market report on the basis of application, distribution channel, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Hypogammaglobulinemia

  • CIPD

  • Immunodeficiency Diseases

  • Congenital AIDS

  • Chronic Lymphocytic Leukemia

  • Myasthenia Gravis

  • Multifocal Motor Neuropathy

  • ITP

  • Kawasaki Disease

  • Guillain-barre Syndrome

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Specialty Pharmacy

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait